Entrada Therapeutics, Inc. financial data

Symbol
TRDA on Nasdaq
Industry
Pharmaceutical Preparations
Location
One Design Center Place, Suite 17 500, Boston, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
CycloPorters, Inc. (to 11/10/2016)
Latest financial report
10-Q - Q3 2024 - Nov 5, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 355 % +15.6%
Debt-to-equity 55.2 % -39.1%
Return On Equity 16.1 %
Return On Assets 10.4 %
Operating Margin 26.9 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 37.4M shares +12.1%
Common Stock, Shares, Outstanding 37.4M shares +12.2%
Entity Public Float 431M USD +57.1%
Common Stock, Value, Issued 4K USD +33.3%
Weighted Average Number of Shares Outstanding, Basic 40.6M shares +22.1%
Weighted Average Number of Shares Outstanding, Diluted 40.6M shares +16.8%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 215M USD -55.3%
Research and Development Expense 120M USD +37.7%
General and Administrative Expense 37.3M USD +11.1%
Operating Income (Loss) 57.8M USD -255%
Income Tax Expense (Benefit) 21.5M USD +89.3%
Net Income (Loss) Attributable to Parent 55M USD -140%
Earnings Per Share, Basic 1.68 USD/shares -133%
Earnings Per Share, Diluted 1.65 USD/shares -134%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 78M USD +50.4%
Marketable Securities, Current 162M USD
Cash, Cash Equivalents, and Short-term Investments 449M USD +27.1%
Assets, Current 465M USD +21.5%
Property, Plant and Equipment, Net 10.8M USD -2.32%
Operating Lease, Right-of-Use Asset 73.8M USD -12.2%
Other Assets, Noncurrent 746K USD -75%
Assets 555M USD +14.3%
Accounts Payable, Current 1.29M USD +71.8%
Employee-related Liabilities, Current 6.58M USD +28.2%
Accrued Liabilities, Current 13.4M USD +39.6%
Liabilities, Current 70.6M USD -57.3%
Operating Lease, Liability, Noncurrent 53.6M USD -14.2%
Liabilities 132M USD -44.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax 972K USD
Retained Earnings (Accumulated Deficit) -130M USD +29.6%
Stockholders' Equity Attributable to Parent 422M USD +71.3%
Liabilities and Equity 555M USD +14.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -25.5M USD -113%
Net Cash Provided by (Used in) Financing Activities 206K USD -98.9%
Net Cash Provided by (Used in) Investing Activities 26.1M USD
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 37.4M shares +12.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 834K USD -99.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 82M USD +46.9%
Deferred Tax Assets, Valuation Allowance 77.9M USD +35.7%
Deferred Tax Assets, Gross 102M USD +57.9%
Operating Lease, Liability 68.2M USD +163%
Depreciation 3.53M USD +38.8%
Payments to Acquire Property, Plant, and Equipment 838K USD -49.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 56.4M USD -135%
Lessee, Operating Lease, Liability, to be Paid 94.6M USD +246%
Property, Plant and Equipment, Gross 19.3M USD +19.2%
Operating Lease, Liability, Current 7.74M USD +16.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 13.2M USD +38.6%
Lessee, Operating Lease, Liability, to be Paid, Year One 13.1M USD +41.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure +105%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 26.4M USD +1748%
Lessee, Operating Lease, Liability, to be Paid, Year Three 8.83M USD +2.04%
Deferred Tax Assets, Operating Loss Carryforwards 3.62M USD -88.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 9.08M USD
Operating Lease, Payments 2.28M USD +24.1%
Additional Paid in Capital 552M USD +27.6%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 17.1M USD +40.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%